Embolization Coils

Global Embolization Coils Market to Reach US$2.4 Billion by 2030

The global market for Embolization Coils estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Detachable Coil, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Pushable Coil segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$492.2 Million While China is Forecast to Grow at 8.8% CAGR

The Embolization Coils market in the U.S. is estimated at US$492.2 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$504.0 Million by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Embolization Coils Market – Key Trends & Drivers Summarized

Why Are Embolization Coils Gaining Strategic Ground in Minimally Invasive Therapies?

Embolization coils have emerged as a critical component in interventional radiology and vascular therapies due to their effectiveness in occluding blood vessels to treat a range of conditions, including aneurysms, arteriovenous malformations (AVMs), gastrointestinal bleeds, and hypervascular tumors. Their minimally invasive deployment, combined with precision targeting, offers significant clinical benefits such as reduced recovery time, minimized surgical trauma, and improved patient outcomes.

These coils are inserted via catheterization under imaging guidance and are designed to induce thrombosis within the targeted vessel. The growing preference for embolotherapy over open surgical procedures is expanding their adoption across neurology, oncology, urology, and gastrointestinal specialties. Advancements in imaging technologies and microcatheter designs have enabled physicians to treat even peripheral vascular malformations and visceral aneurysms with unprecedented accuracy.

The increasing prevalence of chronic diseases, such as cancer and vascular disorders, is a major factor driving demand. In particular, liver and renal cancers often require embolization to starve tumors of their blood supply either as a standalone palliative procedure or in combination with chemoembolization. Similarly, coils are widely used to manage cerebral aneurysms, especially in patients who are poor candidates for craniotomy or surgical clipping.

How Are Materials Science and Design Innovations Transforming Coil Efficacy?

Significant innovations in coil materials, architecture, and delivery mechanisms are redefining the therapeutic scope and performance of embolization procedures. The evolution from bare platinum coils to complex hybrid structures composed of platinum, tungsten, hydrogel, and polymeric overlays has expanded the range of clinical indications and improved occlusion durability. These advanced materials provide enhanced radiopacity, controlled thrombogenicity, and improved coil conformability.

Hydrogel-coated coils, for example, offer a key advantage by expanding after placement to fill the vascular space more completely, thus promoting faster and more stable clot formation. Their use has gained traction in intracranial aneurysm management, where complete filling and durable occlusion are essential to reduce the risk of aneurysm recurrence. Furthermore, detachable coil systems have significantly improved procedural safety and placement precision by allowing interventionalists to reposition or retract coils before final deployment.

Innovations in coil shape and flexibility are also notable. New 3D and complex helical configurations increase the packing density and promote better anchoring within the vessel, especially in wide-necked aneurysms or irregular cavities. These advancements, combined with enhanced microcatheter compatibility, have facilitated access to distal or tortuous anatomy that was previously challenging to reach. Such improvements are particularly critical in neurovascular interventions, where precision and navigability are paramount.

Which Clinical Applications Are Driving Large-Scale Adoption Across Healthcare Systems?

The most prominent clinical application of embolization coils is in the treatment of intracranial aneurysms, where endovascular coiling has become the standard of care for a significant portion of patients. Compared to surgical clipping, coiling offers a lower procedural risk and faster recovery, making it especially suitable for older populations or those with comorbidities. Neuro-interventional procedures have thus become a dominant segment in terms of coil usage, supported by an increasing number of stroke and aneurysm management centers globally.

In oncology, embolization coils are integral to transarterial embolization (TAE) and transarterial chemoembolization (TACE) procedures used to manage unresectable hepatic and renal tumors. By occluding blood flow selectively to tumor-feeding arteries, these coils help shrink tumors or enhance the efficacy of localized chemotherapy. Growing global cancer incidence—particularly liver cancer associated with hepatitis B/C and lifestyle factors—has heightened the relevance of this application.

Peripheral vascular interventions are also seeing significant uptake. Embolization coils are routinely used to manage varicoceles, pelvic congestion syndrome, and arteriovenous fistulas. In trauma cases, they are used to control internal bleeding without the need for open surgery, offering vital support in emergency settings. Gastrointestinal bleeds and postpartum hemorrhages are further extending the use of coils in interventional radiology and OB-GYN care.

What Is Fueling the Global Growth of the Embolization Coils Market?

The growth in the embolization coils market is driven by several factors including the rising burden of vascular and oncological conditions, expanding access to image-guided minimally invasive procedures, improvements in embolic coil technology, and supportive reimbursement frameworks in developed healthcare systems.

Chronic disease prevalence is the foremost market driver. A global rise in aging populations, coupled with lifestyle-induced risk factors such as obesity, hypertension, and diabetes, is accelerating the incidence of aneurysms and vascular malformations. Concurrently, higher detection rates due to the increasing use of diagnostic imaging such as CT angiography and MRI are leading to more elective and urgent interventions involving embolization coils.

Technological advancement is another critical enabler. Modern coils are engineered with enhanced deployment control, complex conformations for better packing, and biocompatible coatings that minimize inflammation and migration risk. These design improvements are not only increasing procedural success rates but also reducing recurrence and retreatment needs, thereby improving overall patient prognosis.

Healthcare infrastructure upgrades across emerging economies are playing a pivotal role in market expansion. As nations invest in interventional radiology equipment and training, embolization coil procedures are becoming more widely available. In parallel, international medical device manufacturers are actively expanding their portfolios in Asia-Pacific, Latin America, and the Middle East to cater to the growing interventional oncology and vascular care demands.

Reimbursement policy evolution also supports growth. In high-income countries, embolization therapies are increasingly recognized under insurance coverage, particularly when used as first-line treatment for aneurysms or as part of integrated oncology care. Hospitals and ambulatory surgery centers benefit from improved cost-effectiveness due to shorter patient stays and reduced surgical complications.

Taken together, these clinical, technological, and policy drivers are catalyzing the global embolization coils market`s expansion. The convergence of aging demographics, medical device innovation, minimally invasive treatment preferences, and improved clinical protocols ensures that embolization coils will remain a cornerstone of endovascular therapy well into the future.

SCOPE OF STUDY:

The report analyzes the Embolization Coils market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Detachable Coil, Pushable Coil); Application (Neurology Application, Oncology Application, Peripheral Vascular Disease Application, Cardiology Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Acandis GmbH & Co. KG
• AngioDynamics, Inc.
• Asahi Intecc Co., Ltd.
• B. Braun Melsungen AG
• Balt Extrusion
• Boston Scientific Corporation
• Cardinal Health, Inc.
• Cook Medical LLC
• EndoShape, Inc.
• Guerbet Group
• InspireMD, Inc.
• Johnson & Johnson (DePuy Synthes)
• Kaneka Corporation
• Medikit Co., Ltd.
• Medtronic plc
• Merit Medical Systems, Inc.
• MicroPort Scientific Corporation
• Penumbra, Inc.
• Shape Memory Medical Inc.
• Stryker Corporation
• Terumo Corporation

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.